<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115848">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717768</url>
  </required_header>
  <id_info>
    <org_study_id>TT-002</org_study_id>
    <nct_id>NCT01717768</nct_id>
  </id_info>
  <brief_title>Oral Testosterone for the Treatment of Hypogonadism</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Dose Response Study of Oral Testosterone in Subjects With Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TesoRx Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TesoRx Pharma, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low testosterone is a condition that occurs when the body is unable to produce sufficient
      quantities of testosterone. The medical name for low testosterone is hypogonadism.
      Hypogonadism can be caused by many factors. Symptoms include: decrease in libido, lack of
      energy and mood swings. The goal of testosterone replacement therapy is to return
      testosterone levels to the normal range and relieve symptoms.

      The purpose of this study is to evaluate the ability of TSX-002, which is testosterone
      provided in easy to swallow capsules, to maintain serum (blood) testosterone levels within
      the normal range in hypogonadal men. This will be determined by blood sampling at specified
      times during the study. The study is also intended to evaluate the tolerability of TSX-002,
      which will be taken orally twice per day for 15 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total serum testosterone</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subject achieving a 24-hour average total serum testosterone concentration (Cavg,0-24h) in the range of 300 to 1050 ng/dL after 15 days of BID treatment with TSX-002</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with total serum testosterone levels above normal range</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of TSX-002</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>frequency and severity of adverse events
clinically significant changes in laboratory parameters
vitals and electrocardiograms (ECGs)
physical examinations
adverse events leading to discontinuation of study drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>TSX-002 (oral testosterone) 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of TSX-002 120 mg BID for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSX-002 (oral testosterone) 240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of TSX-002 240 mg BID for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TSX-002</intervention_name>
    <description>TSX-002 are capsules with testosterone as the active ingredient.</description>
    <arm_group_label>TSX-002 (oral testosterone) 120 mg</arm_group_label>
    <arm_group_label>TSX-002 (oral testosterone) 240 mg</arm_group_label>
    <other_name>Testosterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior documentation of a diagnosis of hypogonadism as evidenced by a screening serum
             testosterone &lt; 300 ng/dL (based on the average of 2 morning samples taken at least 1
             week apart)

          -  Men over the age of 18 years with a body mass index (BMI) &lt; 39.0 kg/m2 and weighing â‰¥
             55 kg

          -  Hemoglobin levels at screening and baseline &gt; 12.5 g/dL

          -  Testosterone treatment not contraindicated

          -  No evidence of suspected reversible hypogonadism

          -  Willing to abstain from current treatment for hypogonadism in accordance with
             approved labeling to facilitate an appropriate washout period before study
             participation (for nondepot formulations of testosterone only)

          -  Understands the requirements of the study and voluntarily consents to participate in
             the study

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Hamdy, MD</last_name>
    <role>Study Director</role>
    <affiliation>TesoRx Pharma, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joel Barra</last_name>
    <phone>562-201-2632</phone>
    <email>jbarra@airesearch.us</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology Group of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Barra</last_name>
      <phone>562-201-2632</phone>
    </contact>
    <contact_backup>
      <last_name>Raquel Izumi, PhD</last_name>
      <phone>650-862-5118</phone>
    </contact_backup>
    <investigator>
      <last_name>John Kowalczyk, DO, FACOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 2, 2013</lastchanged_date>
  <firstreceived_date>October 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypogonadism</keyword>
  <keyword>Gonadal Disorders</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Testosterone enanthate</keyword>
  <keyword>Testosterone undecanoate</keyword>
  <keyword>Testosterone 17 beta-cypionate</keyword>
  <keyword>Methyltestosterone</keyword>
  <keyword>Androgens</keyword>
  <keyword>Hormones</keyword>
  <keyword>Hormones, Hormone Substitutes, and Hormone Antagonists</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Anabolic Agents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Hormones, Hormone Substitutes, and Hormone Antagonists</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
